[Gene therapy in rheumatoid polyarthritis: perspectives].
THE CONCEPT OF GENE THERAPY: Gene therapy is applicable in diseases involving several genes such as rheumatoid arthritis. Gene transfer is the insertion in vivo of genetic material necessary to produce a molecule with therapeutic action. This strategy is currently in experimental stages; feasibility studies in humans are in the preliminary stage. SEVERAL TARGETS: In experimental models of rheumatoid arthritis, the most widely studied target genes are those which code for inflammation inhibitors such as IL-1 receptor antagonists or anti-inflammatory cytokines (IL-4, IL-10, IL-13). Another interesting target would concern genes coding for molecules inhibiting joint destruction (for example metalloprotease inhibitors). VECTORS: The development of high-performance vectors (both viral and nonviral vectors) will greatly improve the expected benefit/risk potential of gene therapy in general. IN RHEUMATOID ARTHRITIS: The particular problem in rheumatoid arthritis is the choice of the transfection site. An articular site would require multiple injections in the different affected joints. A systemic approach would take into account the general disseminated nature of the disease.
Service de Rhumatologie, CHU Avicenne, Bobigny, INSERM U 477, Hôpital Cochin, Paris.
N
N
Bessis
M C
MC
Boissier
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000628:therapy*; D016207:Cytokines / Q000235:genetics / Q000627:therapeutic use; D004195:Disease Models, Animal; D005240:Feasibility Studies; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D007267:Injections; D007270:Injections, Intra-Articular; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors / Q000235:genetics; D018570:Risk Assessment; D014162:Transfection
D016207:Cytokines; D017472:Receptors, Interleukin-1
Thérapie génique dans la polyarthrite rhumatoïde: perspectives.